Biogen Inc. and MannKind Corporation: SG&A Spending Patterns Compared

SG&A Spending Trends: Biogen Inc. vs. MannKind Corporation

In the competitive landscape of the pharmaceutical industry, understanding spending patterns is crucial. From 2014 to 2023, Biogen Inc. and MannKind Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Biogen's SG&A expenses have consistently been higher, peaking in 2021 with a 38% increase from 2014. This reflects their aggressive market strategies and expansive operations. In contrast, MannKind's SG&A expenses have been more volatile, with a notable 130% increase in 2015, followed by fluctuations that suggest strategic shifts and adaptation to market challenges. By 2023, MannKind's expenses rose by 19% from 2014, indicating a more stabilized approach. These trends highlight the differing strategies of a biotech giant versus a smaller pharmaceutical player, offering insights into their operational priorities and market positioning.